Jul 27, 2020
AZD0466 trial opens MD Anderson Cancer Center as a site
Melbourne, Australia; 27 July 2020: Starpharma (ASX: SPL, OTCQX: SPHRY) today announced the opening of the MD Anderson Cancer Center as a further trial site for the phase 1 trial of AZD0466, AstraZeneca’s first DEP® product.
The University of Texas MD Anderson Cancer Center (MDACC) is one of the world's most respected cancer hospitals and is based in Houston, Texas. It is the largest cancer center in the US and is devoted exclusively to cancer patient care, research, education and prevention. The Center conducts hundreds of clinical trials to test new oncology treatments.
AZD0466 is a highly optimised nanomedicine formulation of AstraZeneca’s novel dual Bcl2/xL inhibitor which utilises Starpharma’s DEP® technology. The development of AZD0466 is being progressed under a multi-product licence whereby Starpharma is eligible to receive development, launch and sales milestones.
Dr Jackie Fairley, Starpharma CEO, commented: “We’re pleased to see the ongoing progress of the AZD0466 trial. It is exciting to have this highly novel DEP®-based product being made available to patients at this leading international cancer center.”
AZD0466 is a dendrimer-based formulation of a novel dual Bcl2/xL inhibitor developed under Starpharma’s multi-product DEP® licence with AstraZeneca. AZD0466 utilises DEP® to improve the formulation characteristics and therapeutic index of the anti-cancer agent and is currently in a phase 1 trial in the US. AZD0466 is described as having the potential to be a ‘best-in-class’ agent with a broad opportunity in solid and haematological tumours (blood cancers) due to its ability to target both Bcl2 and Bcl/xL. AZD0466 has demonstrated excellent anti-cancer activity in a wide range of preclinical tumour models including Acute Myeloid Leukemia (AML), Acute Lymphoblastic Leukemia (ALL), Non-Hodgkin’s Lymphoma and Small Cell Lung Cancer (SCLC).
Download ASX Announcement: AZD0466 trial opens MD Anderson Cancer Center as a site (PDF, 52kb)